| STAT signaling in the pathogenesis and therapy of acute myeloid leukemia and myelodysplastic syndromes |
|
Neoplasia |
Myelodysplastic Syndromes (MDS) |
| Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates |
|
Blood Advances |
Aplastic Anemia |
| Thrombosis at Unusual Sites: Focus on Myeloproliferative Neoplasms and Paroxysmal Nocturnal Hemoglobinuria |
|
Hamostaseologie |
Myeloproliferative Neoplasms (MPN), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study |
|
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
| Genome sequencing in the management of myelodysplastic syndromes and related disorders |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Diagnosis of myelodysplastic syndromes: the classic and the novel |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Treatment of high-risk myelodysplastic syndromes |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Treatment of lower-risk myelodysplastic syndromes |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Current landscape of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitors and regulators |
|
Therapeutic Advances in Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Pegcetacoplan: the first and only C3-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria |
|
Expert Review of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
